Prostate cancer progression also depends on its ability to form new blood vessels, and calcitriol inhibits angiogenesis by reducing the expression of pro-angiogenic factors such as VEGF (vascular endothelial growth factor) and HIF-1α (hypoxia-inducible factor 1-alpha) [23]. Here, VEGFA is linked to prostate carcinoma.